Sartorius Stedim Biotech S.A. provided earnings guidance for the fiscal year 2022. The company expects consolidated sales revenue growth is now expected to be in the lower half of the range of around 15% to 19% projected so far, with non-organic growth from acquisitions anticipated to contribute about 2% points.